BridgeBio Pharma (BBIO) Return on Assets (2019 - 2026)

BridgeBio Pharma has disclosed Return on Assets across 8 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Assets for Q1 2026 came in at 0.01%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY), and the FY2025 annual result was 0.01%, changed 0.0% from the prior year.
• Return on Assets came in at 0.01% for Q1 2026 at BridgeBio Pharma, up from 0.01% in the prior quarter.
• In the past five years, Return on Assets ranged from a high of 0.01% in Q2 2024 to a low of 0.01% in Q4 2023.
• The 5-year median for Return on Assets is 0.01% (2025), against an average of 0.01%.
• Peak annual rise in Return on Assets reached 0 bps in 2022, while the deepest fall reached 0 bps in 2022.
• BridgeBio Pharma's Return on Assets stood at 0.01% in 2022, then slipped by 29 bps to 0.01% in 2023, then surged by 40 bps to 0.01% in 2024, then fell by 6 bps to 0.01% in 2025, then rose by 17 bps to 0.01% in 2026.
• The last three Return on Assets figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.